DLBS1033 is a standardized protein fraction extracted from Lumbricus rubellus using a patented extraction process. It contains eight major proteins with molecular weights under 100 kDa, identified as Lumbrokinase, partial Lumbrokinase, Fibrinolytic protease and Superoxide Dismuthase. Those proteins which give DLBS1033 its distinctive characteristics, referred to as LLP (Lumbricus Low Molecular Weight Proteins). DLBS1033 has been shown to have anti-thrombosis activities and thrombolytic activity.
Product Overview
Botanical origin
Lumbricus rubellus
Type of extract
Dry extract
Product Specification
1. Premium Quality and Standardization
DLBS1033 is a standardized protein fraction that has been through a patented extraction technology and is made to meet quality specifications.
2. Manufactured in a Certified Facility
Produced in a facility with GMP, CPOTB, IEBA and ISO22000 certifications, ensuring top-tier quality.
Guaranteed Halal through the implementation of the Halal Assurance System.
3. Proven Safety Through Rigorous Studies
Acute and subchronic toxicity studies exhibited DLBS1033 as a practically non-toxic substance, indicated by the LD50 value greater than 5 g/kg body weight. Furthermore, a 90 days study of DLBS1033 revealed no changes in the behaviour, activity, blood profile, blood biochemistry, weight, urine, or abnormalities in animal organs.
Chronic toxicity studies exhibited DLBS1033 is safe for long term use.
The results of teratogenicity studies, which assess safety during pregnancy, indicate DLBS1033 as a non-teratogenic substance.
4. Proven Benefits through Pre-clinical and Clinical Study
Pre-clinical studies have identified DLBS1033 as an antithrombotic and thrombolytic agent through several mechanisms. It also highlighted its significant role in downregulating inflammatory markers and its effects on reducing oxidative stress. Additionally, the ex vivo study indicated that DLBS1033 prolonged blood clotting time, further confirming its antithrombotic properties.
Clinical studies have demonstrated that DLBS1033 significantly reduces platelet aggregation. Additionally, research involving patients with atherosclerosis indicated a potential reduction in the risk of cardiovascular events. In a study focused on patients with acute ischemic stroke, DLBS1033 exhibited a hemostatic profile comparable to that of aspirin and clopidogrel, which resulted in improved clinical outcomes. Furthermore, another study suggests that DLBS1033 could be a promising treatment option for cerebrovascular diseases, including Peripheral Artery Disease (PAD).
Key Feature of the Product
Many studies of earthworms have proven that it has anti-thrombosis and thrombolytic activities both in vitro and in vivo. In DLBS1033, L. rubellus has been clinically proven to have antithrombotic and thrombolytic properties that improve neurological function in acute ischemic stroke.
Empirical benefit
The traditional uses of Lumbricus rubellus are largely based on its perceived health benefits, including improving circulation, reducing inflammation, aiding in detoxification, and supporting respiratory health. Earthworms have been used in Traditional Chinese Medicine to promote blood circulation and remove blood stasis. They are believed to invigorate the blood and help with conditions like blood clots or poor circulation.
Proven effective as anti-thrombosis activities and thrombolytic activity
Several clinical studies have evaluated the safety and efficacy of DLBS1033. One study involving 19 healthy volunteers demonstrated that DLBS1033 significantly reduced platelet aggregation. Additionally, another study involving patients with atherosclerosis showed a significant decrease in platelet aggregation after two and four weeks treatment with DLBS1033. Furthermore, a separate study involving patients with acute ischemic stroke concluded that DLBS1033 had a comparable hemostatic profile (prothrombin time, thrombin time, aPTT, and fibrinogen levels) to aspirin and clopidogrel, leading to improved clinical outcomes. Another study showed DLBS1033 improved the Ankle-Brachial Index (ABI) in patients with intermittent claudication, suggesting that DLBS1033 could be a promising treatment for cerebrovascular diseases, including Peripheral Artery Disease (PAD).
Health Benefit
Store in a tightly closed container, at a temperature below 30°C, in a dry place and avoid direct sunlight.
Storage Conditions
Product information of Disolf